Stroke recovery may not end when blood flow is restored to major brain vessels. Despite successful mechanical clot removal achieving vessel reopening in over 80% of cases, roughly half of stroke patients still face significant disability, suggesting that restoring circulation to large arteries doesn't guarantee adequate blood flow reaches damaged brain tissue at the cellular level.
This randomized trial examined whether delivering the clot-dissolving drug alteplase directly into brain arteries after mechanical thrombectomy could improve outcomes beyond vessel reopening alone. Among 196 patients, those receiving intra-arterial alteplase within six hours of stroke onset showed enhanced functional recovery compared to standard care. The intervention specifically targeted the gap between macrovascular patency and tissue-level perfusion, addressing residual clots in smaller vessels that mechanical devices cannot reach.
This approach represents a nuanced evolution in acute stroke treatment protocols. Current guidelines emphasize rapid vessel reopening as the primary endpoint, but emerging evidence suggests this binary success metric may be insufficient. The findings align with growing recognition that stroke recovery involves multiple physiological processes beyond initial recanalization, including inflammation control, neuroprotection, and microvascular restoration. However, alteplase carries bleeding risks that must be weighed against potential benefits, particularly in patients who have already undergone invasive procedures. The study's relatively small size and single-center design warrant cautious interpretation until larger multicenter trials confirm these preliminary results. If validated, this dual-intervention strategy could refine treatment algorithms for the estimated 700,000 Americans experiencing ischemic strokes annually, potentially improving functional outcomes for patients who achieve vessel reopening but remain neurologically impaired.